Compare Abeona Therapeutics Inc (ABEO) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Firy Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Firy Inc. trades at $9.98 (market cap $159.51M). The key difference: Abeona Therapeutics Inc is far larger — about 2.6× Firy Inc.'s market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | FIRY | |
|---|---|---|
Market Cap | $421.19M | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $12.45 |
52-Week Low | $4.17 | $2.28 |
Enterprise Value | $276.10M | $103.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
FIRY trades at $9.98, down 4.77% in the last 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth and a slight earnings beat, yet maintains negative net income margins and cash flow challenges. Recent news includes a legal victory awarding $719 million and a rebrand from Skillz Inc.
Outlook remains cautious due to persistent losses and cash burn, though the legal win provides a liquidity boost. Risks include high SG&A costs and competitive pressures, while analyst sentiment is mixed with a majority hold rating. Investors should weigh the potential from strategic shifts against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
